Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems

Supportive Care in Cancer

Volumn 22, Issue 5, 2014, Pages 1363-1373

  Oster, Gerry ^a   Lamerato, Lois ^b   Glass, Andrew G ^c   Richert Boe, Kathryn E ^c   Lopez, Andrea ^a   Chung, Karen ^d   Richhariya, Akshara ^d   Dodge, Tracy ^c   Wolff, Greg G ^b   Balakumaran, Arun ^d   Edelsberg, John ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c KAISER PERMANENTE   (United States)

^d AMGEN INC   (United States)

Author keywords

Bisphosphonates; Breast neoplasms; Lung neoplasms; Neoplasm metastasis; Prostatic neoplasms

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; RISK ASSESSMENT; SPINAL CORD COMPRESSION; TREATMENT DURATION;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 84897519395     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2094-y     Document Type: Article

References (16)

1. Zometa® (2012) (zoledronic acid) prescribing information, Novartis Pharmaceuticals Corporation. East Hanover, NJ. http://www.pharma.us.novartis. com/product/pi/pdf/Zometa.pdf Accessed 12 June 2013
2. Aredia® (2012) (pamidronate disodium) prescribing information, Novartis Pharmaceuticals Corporation. East Hanover, NJ. http://www.pharma.us. novartis.com/product/pi/pdf/aredia.pdf Accessed 12 June 2013
3. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391 (Pubitemid 30159858)
4. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057 (Pubitemid 46606220)
5. Van Poznak CH, Temin S, Yee GC, Janjan NA,Barlow WE, Biermann JS, Bosserman LD,Geoghegan C,Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, American Society of Clinical Oncology (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 9:1221-1227
6. The NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (version 3.2013). © National Comprehensive Cancer Network, Inc. http://www.nccn.org Accessed 12 June 2013
7. The NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (version 2.2013). © National Comprehensive Cancer Network, Inc. http://www.nccn.org Accessed 12 June 2013
8. The NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (version 3.2013). © National Comprehensive Cancer Network, Inc. http://www.nccn.org Accessed 12 June 2013
9. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2008) Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13:494-502 (Pubitemid 351872867)
10. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113:1438-1445
11. Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A (2011) Treatment persistence withmonthly zoledronic acid is associatedwith lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer 11:177-183
12. Mortimer JE, Schulman K, Kohles JD (2007) Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. Clin Breast Cancer 7:682-689 (Pubitemid 47344730)
13. Henk HJ, Kaura S (2012) Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. J Med Econ 15:185-194
14. Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L (2011) The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis 14:79-84
15. Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND (2012) Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology 80:293-298
16. Henk HJ, Kaura S, Teitelbaum A (2012) Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. JMed Econ 15:195-204